Synergies between ENCePP and Health Technology Assessment

Anne Solesse, Post-registration studies department, HAS, France
Joint Action

A total of 34 government appointed organisations from 23 EU Member States, Croatia and Norway and a large number of relevant non-for-profit organisations that produce or contribute to HTA

Main objective

to put into practice an effective and sustainable HTA collaboration in Europe that brings added value at the European, national and regional level
EUnetHTA 2010-12: Work Packages

1. Coordination
2. Dissemination
3. Evaluation
4. Core HTA including adaptation
5. Relative Effectiveness Assessment (REA) of Pharmaceuticals
6. Information management system
8. Strategy development (Business model for sustainability including capacity building to do HTA)
Current situation

• Some new technologies (medicines, other HT)
  – Identified evidence gaps and need (common for several HTA bodies) for additional evidence
  – Data requirements: not clearly specified, not coordinated, not harmonised
  – Multiple studies with heterogeneous designs performed to answer similar requests
  – Inconsistent results

• Lack of critical mass of robust data to reduce uncertainty

• Waste of time and money
Expected benefit from WP7

- **Update** information on new technologies and identify evidence gaps
- Update information on additional data requirements in the countries where the technology was assessed
- Possibility for **collaboration** to harmonise data requirements
- Studies (multinational or not) with **comparable** designs and outcomes
- Better **quality** information provided to decision makers at the time of the re-assessment
Action Plan - Objectives

• Define **criteria** for selection of technologies that need additional evidence generation

• **Share** information (database) on new technologies
  – Evidence gaps
  – recommendation for additional data collection (research question, type of study),
  – HTA guidance and coverage and reimbursement status

• **Registry** of planned or ongoing clinical studies
  – PICO structure
  – Minimum dataset development
Deliverables

• **Criteria**
  – to select, among new technologies, the ones for which additional data collection will be useful and efficient

• **Database**
  – User friendly IT functionalities
  – Visual structure with rapid information access
Perspectives

- Standardisation of further research recommendations in HTA reports

- Facilitating collaboration between sponsors/funders on agreed core protocols for a technology of interest

- Effective collaboration to set up policy relevant studies
  - Individual studies based on common core protocols
  - Multinational studies
EVIDENT Database

• content: information on
  – health technologies (assessment status, evidence gaps, research questions, required additional studies, coverage decision status)
  – planned studies (a minimum information necessary for establishing collaboration: PICO, protocols, results of studies, etc; )

• scope:
  – all types of technologies (drugs, devices, procedures)
  – studies requested by European HTA bodies following a HTA,
  – studies still in the development phase

• goal: support European collaboration and help avoiding duplication of studies, promote global analysis of results (critical mass of consistent data)
**EVIDENT** vs. **ENCePP**

((register of studies)

**Scope**

- **EVIDENT**
  - all types of technologies (drugs, devices, procedures)
  - studies requested by European HTA bodies following a HTA,
  - studies still in the development phase
  - Restricted access

- **ENCePP**
  - Only drugs
  - Any pharmacoepidemiology and pharmacovigilance studies
  - Any phase of the study
  - Public access

**Partial overlap of studies intended to be registered**
EVIDENT vs. ENCePP

content

- information on
  - health technologies (assessment status, evidence gaps, research questions, required additional studies, coverage decision status)
  - planned studies (a minimum information necessary for establishing collaboration: PICO, protocols, results of studies, etc; )

- information on
  - planned and ongoing studies
    - identification of the drug, the sponsor, the investigator, etc...
    - description of the study design, the study progress and the results
Collaboration EVIDENT/ENCePP

- **First steps:**
  - Participation of ENCePP Public consultation on Evident
  - ENCePP representative attending the next WP7 Face to Face meeting next September

- **Further development:**
  - Encapsulated search on ENCePP through EVIDENT
  - Alert in EVIDENT on new studies being entered in ENCePP
  - Access to EVIDENT for ENCePP members to be discussed